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In this report, we further characterized the effects of silibinin (SbN), derived from milk thistle extract, and
Legalon-SIL (SIL), a water-soluble derivative of SbN, on T cell metabolism and HIV infection. We assessed the
effects of SbN and SIL on peripheral blood mononuclear cells (PBMC) and CEM-T4 cells in terms of cellular
growth, ATP content, metabolism, and HIV infection. SIL and SbN caused a rapid and reversible (upon removal)
decrease in cellular ATP levels, which was associated with suppression of mitochondrial respiration and
glycolysis. SbN, but not SIL inhibited glucose uptake. Exposure of T cells to SIL (but not SbN or metabolic
inhibitors) during virus adsorption blocked HIV infection. Thus, both SbN and SIL rapidly perturb T cell
metabolism in vitro, which may account for its anti-inﬂammatory and anti-proliferative effects that arise with
prolonged exposure of cells. However, the metabolic effects are not involved in SIL's unique ability to block
HIV entry.
& 2013 Elsevier Inc. All rights reserved.
Introduction
Natural products offer wide chemical diversities that are touted
in complementary and alternative medicinal practices. Moreover,
many pharmaceutical and research drugs are derived from natural
products (Newman and Cragg, 2012). Research on natural products
often focuses on their effects on human cells, and how these
effects translate into anti-infective, anti-proliferative, and anti-
inﬂammatory properties of the compounds.
There are approximately 34 million people currently living with
HIV-1 infection, and nearly 30 million people have died of AIDS-
related causes since the beginning of the epidemic (UNAIDS, 2011,
2012). However, even with effective virus control by antiretroviral
therapy (ART), many HIVþ subjects suffer from chronic inﬂam-
mation, which is associated with various inﬂammatory diseases
and both AIDS-deﬁning and non-AIDS-deﬁning cancers (Cutrell
and Bedimo, 2013; Dubrow et al., 2012). Thus, there is a need to
develop anti-inﬂammatory therapies for HIVþ subjects.
Many natural products have been shown to have anti-
inﬂammatory properties (Asres et al., 2005). One such product,
silymarin (SM), derived from the seeds of the milk thistle plant
(Silybum marianum (L.) Gaertn.), has been consumed orally for
thousands of years since Pedanius Dioscorides ﬁrst described the
plant in Materia Medica (circa 50 AD), and is one of the 10 most
popular botanical medicines consumed by western society (Polyak
et al., 2013a). Many HIVþ patients consume SM with the belief that it
helps protect the liver against damage from certain antiretroviral
drugs and HIV-induced inﬂammation: (http://www.aidsinfonet.
org/fact_sheets/view/735#WHY_DO_PEOPLE_WITH_HIV_USE_SI
LYMARIN). The major component of SM is known as silibinin (SbN),
which is a diastereomeric mixture of two ﬂavonolignans called silybin
A and silybin B. Both SM and SbN block hepatitis C (HCV) infection
in vitro (Polyak et al., 2007, 2010, 2013a,b; Wagoner et al., 2010, 2011).
An intravenous formulation of SbN, where silybin A and silybin B have
been succinated (Supplemental Fig. 1) is known as Legalon-SIL (SIL),
and reduces circulating viral loads in HCV-infected patients (Beinhardt
et al., 2012; Beinhardt et al., 2011; Ferenci et al., 2008; Neumann et al.,
2010). We have recently shown that SIL inhibits human immunode-
ﬁciency virus-1 (HIV-1) infection coincident with dose-dependent
reductions in T-cell activation and proliferation (McClure et al., 2012).
In the current study, we further characterized the effects of SIL and
SbN on T cell metabolism and HIV infection.
Results
SIL causes rapid reductions in intracellular ATP levels prior
to any observable cytostatic effects
We recently showed that SIL inhibits T cell activation and
proliferation coincident with inhibition of HIV infection (McClure
et al., 2012). SIL was shown to slow the proliferation of T cells
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without inducing cell death. In order to gain more insight into the
cytostatic effects of SIL, we ﬁrst performed a kinetic experiment
that included early time points. We compared the effect of SIL on
cell number and viability (by direct cell counting with trypan blue
and by measuring intracellular ATP levels.)
As shown in Fig. 1A, SIL caused dose-dependent inhibition of
CEM T cell growth after 24 h exposure of cells to SIL. However, no
observable effect on cell number was observed when cells were
incubated with SIL for 15 min, 1 h, or 4 h. In direct contrast, SIL
caused signiﬁcant dose-dependent inhibition of intracellular ATP
levels at all time points analyzed, even at the earliest time
analyzed (15 min; Fig. 1B; po0.05). The increase in ATP levels
over time reﬂects cell proliferation. The data indicate that SIL
causes rapid, dose-dependent suppression of intracellular ATP
levels prior to any observable effects on cell growth.
Inhibition of intracellular ATP levels and cell growth requires
continual exposure to SIL and SbN and is rapidly reversible upon
removal of the mixtures
Fig. 2A shows that both SIL and SbN cause rapid, dose-
dependent decreases in ATP levels in both PBMC and CEM T cells
within 10 min of addition. SIL appeared to cause a more rapid and
pronounced decline in ATP levels compared to SbN. Moreover,
intracellular ATP levels rapidly returned to normal upon removal
of SIL (Fig. 2B) and SbN (Fig. 2D), which also correlated with a
restoration of cell growth when the mixtures were removed
(Fig. 2C and E). As previously shown (Wagoner et al., 2011), when
cells were exposed to the mixtures for 24–72 h, SbN was more
toxic to cells than similar doses of SIL. In summary, pulse treat-
ment of T cells with either SIL or SbN does not result in a durable
effect on T cell growth kinetics or intracellular ATP levels. Thus,
these mixtures must be continually present in culture in order to
inhibit cellular ATP levels and cell growth.
SbN and SIL rapidly inhibit mitochondrial respiration and glycolysis
in T cells
Since both SbN and SIL caused such a rapid reduction in cellular
ATP levels, we posited that the mixtures alter T cell metabolism,
similar to previous studies in rodent livers (Colturato et al., 2012;
Detaille et al., 2008; Guigas et al., 2007). Hence, biochemical
studies were ﬁrst performed with SIL on T cell metabolism. Oxygen
consumption rate (OCR, a measure of mitochondrial respiration)
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Fig. 1. SIL causes rapid, early inhibition of intracellular ATP levels. CEM T cells were incubated at the indicated concentrations of SIL and cells were either counted by trypan
blue exclusion (A) or intracellular ATP levels were measured by ATPlite assay (B) at the indicated time points. As compared to untreated cells, all doses of SIL resulted in
signiﬁcant suppression of cellular ATP levels at all time points (po0.05).
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Fig. 2. SbN and SIL cause rapid and reversible decreases in cellular ATP levels. (A) PBMC or CEM T cells were incubated with the indicated concentrations of SIL or SbN and
10 min later, cellular ATP levels were measured. Panels B–E, CEM T cells were exposed to the indicated doses of SIL (panels B and C) or SbN (panels D and E) for 30 min. Cells
were either maintained in the same medium (“SIL/SbN full exposure”), or washed and resuspended in fresh medium containing SIL or SbN (“SIL 30 min-wash- fresh SIL/
SbN”), or in fresh medium without SIL or SbN (“SIL 30 min- wash- no SIL/SbN”). Cells were immediately assayed for ATP content (panels B and D) or incubated for an
additional 72 h before cells counts were measured by trypan blue exclusion (panels C and E).
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and acidiﬁcation of the media arising from extrusion of lactic acid
from cells during glycolysis (extracellular acidiﬁcation rate, ECAR)
were measured using a Seahorse XF24-3 analyzer. Within minutes
of the addition of the mixture, SIL reduced both OCR (Fig. 3A) and
ECAR (Fig. 3B), suggesting that SIL blocks mitochondrial respira-
tion and glycolysis.
We then examined the effects of repeated dosing of SIL and SbN
on mitochondrial respiration and glycolysis. As can be seen in
Fig. 4A, repeated injections of 125 μM of SIL or SbN produced
similar effects on OCR, which appeared ﬁrst as a rapid decline that
slightly recovered, but was persistently suppressed with repeated
dosing. Repeated SIL and SbN dosing led to sustained suppression
of the ECAR (Fig. 4B).
The results demonstrate for the ﬁrst time that both the natural
mixture (SbN) and the chemically modiﬁed mixture SIL suppress
metabolism of human T cells, consistent with previous data
showing that silibinin suppresses hepatic glucose metabolism by
modulating glycolysis, oxidative phosphorylation and gluconeo-
genesis (Colturato et al., 2012; Detaille et al., 2008; Guigas et al.,
2007). The acute effect of SIL and SbN on both glycolysis and
oxidative phosphorylation suggests that these compounds inhibit
glucose utilization upstream of mitochondria, either by interfering
with glucose uptake or by interfering with cytosolic glucose
metabolism. Moreover, the OCR trend following SIL and SbN
administration indicate that cells only partially engage in the
oxidation of alternative cellular energy substrates and compensate
inefﬁciently for the rapid decline in metabolic rate. Thus, we next
determined whether glucose could rescue the inhibitory effects of
SIL or SbN on OCR and ECAR. Cells were ﬁrst equilibrated in
medium with or without 125 mM SIL or SbN. Fig. 5A shows
following the ﬁrst injection of 0.5 mM glucose, SIL and SbN treated
cells had a consistently higher OCR as compared to control cells
(Fig. 5A). The reduction in OCR in response to glucose supple-
mentation is consistent with previous studies showing that some
types of cancer cells decrease their OCR after glucose addition: a
phenotype known as the Crabtree effect (Crabtree, 1929). The
addition of the ATP synthase inhibitor oligomycin, a mitochondrial
phosphorylation inhibitor that abolishes ADP-stimulated respira-
tion in intact mitochondria, suppressed the remaining OCR. Finally,
injection of the uncoupling agent, carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), which dissipates the mitochon-
drial proton gradient, stimulated respiration (OCR) in control and
SIL treated cells by approximately 35%. In contrast, SbN treated
cells did not increase OCR. The data suggest that SIL and SbN do
not inhibit respiration through effects on mitochondrial enzymes
but through the availability of glucose metabolites that fuel
respiration.
Fig. 5B shows that glucose supplementation led to increased
lactic acid production in control cells. SIL and SbN treated cells
did not increase ECAR in response to two injections of glucose.
Addition of oligomycin to control cells led to an initial increase
in ECAR, suggesting that cells upregulated glycolysis to com-
pensate for the respiratory defect. CCCP addition suppressed
ECAR. In contrast, lactic acid production in SIL or SbN treated
cells could not be rescued by glucose, or by the addition of
phosphorylation inhibitor (oligomycin) or uncoupling agent
(CCCP). Cumulatively, the data suggest that SbN and SIL inhibit
the glycolytic pathway.
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Fig. 3. SIL inhibits T cell metabolism. CEM cells were cultured in a Seahorse XF24-3 analyzer in medium containing unbuffered DMEM, 25 mM glucose, 2 mM glutamine, and
1 mM pyruvate. Cells were allowed to equilibrate for 25 min before SIL (1 mM) was injected into the culture chambers (indicated by the arrow). Panel A depicts the oxygen
consumption rate (OCR) over time, while panel B depicts the extracellular acidiﬁcation rate (ECAR).
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Fig. 4. SbN and SIL suppress mitochondrial respiration and glycolysis in T cells. CEM T cells were cultured in a Seahorse XF24-3 analyzer and allowed to equilibrate for 30 min
prior to injection of 125 μM of SIL or SbN at the times indicated by the arrows. (A) Oxygen consumption rate (OCR). (B) Extracellular acidiﬁcation rate (ECAR), presented as
percent change relative to baseline.
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SbN but not SIL inhibits glucose uptake in T cells
To further characterize the metabolic effects of SbN and SIL, we
next determined their effect on glucose uptake in T cells. As shown
in Fig. 6, positive controls glucose and cytochalasin B both inhibited
radiolabeled glucose update. In addition, SbN but not SIL inhibited
glucose uptake, consistent with a previous study where SbN
inhibited glucose uptake in Chinese hamster ovary (CHO) cells
(Zhan et al., 2011). Since SIL and SbN both reduced OCR and ECAR
(Figs. 4 and 5), the data suggest that these changes in OCR and ECAR
were not mediated by reduction in glucose uptake.
SbN and SIL inhibition of intracellular ATP is associated
with inhibition of glycolysis but not glucose uptake
We then asked whether the inhibition of glycolysis and/or
glucose uptake could mimic SbN's and SIL's rapid and reversible
effects on cellular ATP levels shown in Fig. 2. We therefore
compared cellular ATP levels in CEM cells treated with known
inhibitors of glycolysis and glucose uptake. As shown in Fig. 7, only
2-deoxyglucose (2-DG), an inhibitor of glycolysis that inhibits
hexokinase, was capable of inducing rapid inhibition of cellular
ATP levels similar to that of SIL and SbN. Glucose uptake inhibitors
STF-31, Fasentin, and cytochalasin B had no effect on cellular ATP
levels. The results suggested that glycolysis inhibition is associated
with the rapid suppression of cellular ATP levels.
SIL and SbN inhibition of HIV infection is independent of metabolic
inhibition
Because SIL inhibits HIV infection (McClure et al., 2012), and SIL
and SbN inhibit T cell metabolism (as shown above), we wanted to
know whether the metabolic effects of these mixtures are involved
in their anti-HIV effects. Thus, we compared the effect of adding SIL,
SbN, and metabolic inhibitors during the initial stages of HIV-1
infection of CEM T cells. Because both SIL and SbN can inhibit cell
growth when cells are continually exposed to the mixtures for 24 h
or greater (Fig. 2 and McClure et al., 2012; Morishima et al., 2010;
Wagoner et al., 2011), and because SbN (4100 μM) and 2-DG
treatment are toxic to cells when incubated longer than 24 hours
we developed a quantitative infectious center (QIC) assay to
evaluate the effects of transient exposure of cells to drugs during
the early phases of HIV infection (i.e. within the ﬁrst 0.5–2 h) before
the cytostatic and cytotoxic effects are observable.
As shown in Fig. 8 at high dose, both SIL and to a lesser extent,
SbN, inhibited HIV infection in the QIC assay in both CEM T cells
and PBMCs. However, 2-DG and oxamate (an inhibitor of lactic
acid dehydrogenase) had no effect on HIV infection. The data
indicate that the early and rapid effects of SIL and SbN on T cell
metabolism do not appear to be involved in the suppression of
early HIV infection. However, because high doses of SIL and SbN
were used in this experiment, we next exploited the QIC assay to
examine timing and dose-dependency of SIL and SbN addition to
cells during the early stages of HIV infection.
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Fig. 5. Further characterization of SbN and SIL inhibition of T cell metabolism. CEM T cells were plated in unbuffered DMEM, 2 mM glutamine, and no glucose and allowed to
equilibrate for 25 min in the presence or absence (control) of 125 mM SbN or SIL before injections (indicated by arrows) with 0.5 mM glucose (GLUC), 2.5 mM glucose (GLUC),
5 μM oligomycin (OLIGO), and 500 nM CCCP. (A) OCR and (B) ECAR, presented as percent change relative to baseline.
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SIL inhibits HIV entry into T cells
We compared the effect adding and removing SIL or SbN to
CEM T cells before virus exposure or during virus adsorption. As a
control, we exposed cells to the mixtures for the full duration of
the experiment. Fig. 9A and B shows the expected result with the
positive control conditions: continuous exposure of T cells to SIL or
SbN inhibited HIV infection. In contrast, pretreating cells with SIL
or SbN for 1 h, followed by drug removal prior to virus infection
had no effect on HIV infection. This result is consistent with the
rapid recovery of cell growth and ATP levels shown above.
Intriguingly, SIL (Fig. 9A) but not SbN (Fig. 9B) treatment during
the 1-h virus adsorption period caused inhibition of HIV infection
measured as p24 antigen production in culture supernatants.
When virus replication was also measured in the QIC assay on
the same samples, the same effect was observed. That is, SIL, but
not SbN caused dose-dependent inhibition of HIV infection when
added only during the 1-h virus adsorption period (Fig. 9C). These
effects were not unique to the virus isolate (LAI) and cell line
(CEM) used, as SIL potently inhibited many other CXCR4 and CCR5
co-receptor utilizing HIV isolates in PHA-activated PBMCs,
assessed in our QIC assay (Fig. 10). The data indicate that SIL but
not SbN blocks HIV entry into T cells.
Discussion
Cumulatively, the data presented in the current report indicate
that SbN and SIL induce rapid metabolic changes in cells through
modulation of glucose metabolism, yet this phenotype is not
explained solely by a blockade of glucose transport since only
SbN but not SIL inhibits glucose transport. Moreover, the rapid and
reversible effects of SbN and SIL on T cell metabolism (decline of
ATP, OCR, ECAR, glucose uptake (for SbN)) do not appear to be
involved in the early blockade of HIV binding and entry that
appears to be unique to SIL. We propose that the structural
differences between SIL and SbN account for unique effects of
SIL on HIV entry, while the metabolic effects of SIL and SbN may be
involved in the anti-inﬂammatory and anti-proliferative effects
that arise in cells upon prolonged exposure of cells to these
mixtures.
We showed that SIL and SbN induce rapid, reversible effects on
T cell metabolism and that SIL inhibits HIV early in the virus
infection cycle. To further address the early effects of SIL and SbN
on HIV infection, prior to the effects on cell population size (SIL) or
cell toxicity (SbN), we developed a novel quantitative infectious
center (QIC) assay which measures the number of target cells
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infected during a brief virus and drug exposure. SIL but not SbN
inhibited HIV infection potently within a 1 h virus adsorption
phase at 37 1C. The data indicate that SIL has a unique effect in
blocking virus entry. Since other drugs that inhibit cellular
metabolism by blocking glucose uptake or glycolysis did not
inhibit HIV infection in the QIC assay, the early effects of SIL and
SbN on T cell metabolism are not involved in SIL's blockade of virus
entry. Thus, we conclude that a major anti-HIV effect of SIL likely
involves the blocking of virus entry. With prolonged exposure of
cells to these mixtures, the metabolic or activation state of the
target cell becomes compromised, which can also attenuate HIV
replication as previously shown (McClure et al., 2012). Impor-
tantly, SIL is not directly virucidal to HIV-1 (Supplemental Fig. 2),
further supporting the concept that SIL is somehow preventing
virus from entering target cells. An alternative explanation could
be that SbN binds and inhibits the activity of additional metabolic
enzymes with a broader effect while SIL has a more speciﬁc effect.
In support of this, the acute effects of SbN and SIL on reduction of
cellular ATP are fairly similar (Fig. 2A; although SIL causes faster
suppression of ATP levels than SbN; see below), but the long-term
effect (424 h) of SbN is more dramatic, both in terms of cell
number and OCR, than SIL. Further studies are required to deﬁne
exactly how SIL attenuates virus entry, and the cellular targets of
SbN versus SIL.
The apparent lack of reserve metabolic capacity following CCCP
treatment (Fig. 5A) may be the result of two factors. The ﬁrst factor
may be pyruvate, which is an important direct substrate for the
TCA cycle and its exclusion from medium decreases the spare
respiratory capacity (Diers et al., 2012). Since the cells were plated
in XF24 DMEM supplemented with glutamine but not pyruvate at
the start of this experiment, the lack of a reserve respiratory
capacity (i.e. the return of OCR to higher than baseline levels) may
be simply due to the omission of pyruvate in the experiment.
Second, relative to the pre-Oligomycin state, CCCP stimulated
respiration (OCR) in control and SIL treated cells by approximately
35% (Fig. 5A). In contrast, SbN treated cells did not increase OCR.
Thus, the second explanation why CCCP did not induce OCR is that
SbN treated cells may be unable to access and/or utilize glucose.
This potential explanation is supported by the observation that
SbN but not SIL blocked glucose uptake (Fig. 6). These differences
between SIL and SbN might be involved in SbN induced cytotoxi-
city, while SIL is relatively non-toxic.
Since both SIL and SbN have been shown to block HCV entry
during fusion of viral and endosomal membranes (Wagoner et al.,
2010, 2011), we were surprised that SIL was so much more
effective than SbN in inhibiting HIV entry. Moreover, SbN has
been recently shown to block clathrin-mediated endocytosis to
inhibit HCV entry (Blaising et al., 2013). Since HIV enters cells by
fusion of viral and plasma membranes (Gibson and Arts, 2012) as
opposed to viral membrane fusion with cellular endosomal mem-
branes as occurs during HCV entry, it is possible that the unique
role of SIL on HIV entry is dependent on the structure of SIL and its
interaction with the cell surface. However, since HIV may also use
clathrin to enter and trafﬁc within cells (Permanyer et al., 2010;
von Kleist et al., 2011), it remains unclear at present why only very
high doses of SbN block HIV entry (Fig. 8). Moreover, since SIL
decreases cellular ATP levels faster than SbN (Fig. 2A), while SbN is
more toxic than SIL (Fig. 2E), SIL may enter and exit cells via
transporters faster than SbN. Due to its polar structure, SbN may
enter cells via passive diffusion, and be retained in cells, possibly
accounting for its higher toxicity compared to SIL. Again, we
suspect the molecular differences between SIL and SbN account
for their differential interactions with cells in terms of virus entry,
glucose transport, and metabolism.
Our data on inhibition of T cell mitochondrial respiration and
glycolysis by SIL and SbN are consistent with previous studies
showing that silibinin modulates metabolism in rats (Colturato
et al., 2012; Detaille et al., 2008; Guigas et al., 2007), and that
silibinin induces energy stress in colorectal carcinoma cells (Raina
et al., 2013). It is possible that the inhibition of glycolysis observed
in this study is due to an inhibition of glucose-6-phosphate kinase
(Guigas et al., 2007) or pyruvate kinase (Detaille et al., 2008).
Moreover, our results in T cells also corroborate previous studies
showing that SbN inhibits glucose transport across the plasma
membrane in 3T3-L1 adipocytes by perturbing the glucose trans-
porter GLUT4 (Zhan et al., 2011). Moreover, the HIV Nef protein
inhibits GLUT4 mediated glucose transport (Cheney et al., 2011).
We ﬁnd it intriguing that SbN but not SIL inhibited glucose uptake,
yet SIL but not SbN inhibited HIV entry. Given that IL-7 enhances
GLUT1 mediated glucose uptake to facilitate HIV replication
(Loisel-Meyer et al., 2012), it can be surmised that SIL's inhibition
of HIV likely does not involve blockade of glucose uptake. These
observations further underscore the conclusion that the metabolic
effects of SIL and SbN are not involved in SIL's early blockade of
HIV entry. Thus, we hypothesize that the metabolic effects of
silibinin may be mechanistically involved in the anti-inﬂammatory
functions of this class of natural products. In this regard, we have
found that the parent extract, silymarin, regulates the expression
of key cellular genes and signal transduction pathways that are
involved in sensing of the cellular metabolic status (Lovelace and
Polyak, manuscript in preparation). Furthermore, SM also sup-
presses inﬂammation and oxidative stress (Polyak et al., 2013a), all
of which are elevated in chronic immune activation (CIA) asso-
ciated with HIV-1 infection, even in individuals taking combina-
tion antiretroviral therapy (ART). While ART effectively controls
HIV replication, it does not fully control CIA. Thus, the antiviral,
anticancer (Agarwal et al., 2006), anti-inﬂammatory, and antiox-
idant properties of SM may represent a novel approach to combating
virus-induced chronic inﬂammation such as observed for patients
with chronic hepatitis C, HIV, and HIV–HCV co-infection. Nonetheless,
it must be emphasized that this in vitro study does not support (nor
refute) any beneﬁt to HIV-positive individuals by taking silymarin-
containing supplements.
Materials and methods
Chemicals
SbN was purchased from Sigma (St. Louis, MO), and was
solubilized in DMSO (Sigma). SIL was kindly provided by Ralf–
Torsten Pohl (Rottapharm/Madaus, Germany) and solubilized in
PBS. The composition and structures of the mixtures is shown in
Supplemental Fig. 1. Glucose, 2-deoxyglucose, oligomycin, carbo-
nyl cyanide m-chlorophenyl hydrazone (CCCP), cytochalasin B, and
fasentin were also purchased from Sigma. STF-31 was purchased
from Calbichem (EMD Millipore, Billerica, MA).
Cells
Peripheral blood mononuclear cells (PBMC) were isolated from
leukapheresis units from ten healthy HIV-1 seronegative donors
under written informed consent according to University of
Washington Institutional Review Board (UW IRB) regulations. For
the current studies, our work on these archived cryopreserved
PBMC samples was deemed by the UW IRB to not meet the federal
regulatory deﬁnition of “human subject research”, based on the
Code of Federal Regulations (CFR), Title 45, Public Welfare Depart-
ment Of Health And Human Services, Part 46, Protection Of
Human Subjects (45 CFR 46.102(f)). PBMC cryopreserved in liquid
nitrogen were thawed, stimulated with 1.5 mg/ml PHA in IMDM
media supplemented with 10% FBS, and cultured for three days.
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The CEM-T4 cell line (Foley et al., 1965) was obtained through the
AIDS Reagent Program. CEM cells were cultured in IMDM media
supplemented with 10% FBS and maintained in log phase by sub-
culturing every 3–4 days.
Viruses
The viruses (and co-receptor usage) that were used included
HIV-1 LAI (X4) and HIV-1 BAL (R5), V9D6 (R5), RF (X4/R5), JFRL
(R5), UG92029 (X4), and UG92031 (R5), and were obtained
through the AIDS Reagent Program. Viral stocks were generated
in PHA-stimulated PBMC cultures. LAI and BAL represent proto-
type clade B CXCR4 and CCR5 co-receptor-using virus isolates,
respectively. For PBMC-based assays, the infectious titers of the
virus stocks were determined by endpoint dilution in PHA-
stimulated PBMC as described (McClure et al., 2012). The TCID
(tissue culture infectious dose) was derived using the Reed–
Meunch statistical method (Reed and Muench, 1938).
Infection of PBMCs and CEM cells
For HIV-1 replication studies, PBMC were thawed, stimulated
with 1.5 mg/ml PHA in IMDM media supplemented with 10% FBS,
and cultured for three days. PHA-blasts were washed and resus-
pended in IMDM media containing 10% FCS and 10 IU/ml recom-
binant interleukin 2 (IL-2; PeproTek, Rocky Hill, NJ). Cells were
plated and concurrently exposed to SIL or SbN and virus. Residual
virus inoculum was washed out after 24 h and cells fed with fresh
medium containing IL-2 and SIL. Since CEM cells do not require
activation to support HIV infection, the cells were directly infected
with virus in the presence or absence of SIL or SbN. Culture
supernatants were monitored for virus every 3–4 days post-
infection. HIV-1 production by PBMCs and CEM cells was mea-
sured by determining the p24 levels in culture supernatants using
an in-house double-antibody sandwich ELISA (McClure et al.,
2012). A standard curve of absorbance at 450 nm was generated
for each assay plate using a p24 standard obtained from the AIDS
Vaccine Program at the National Cancer Institute (NCI)-Frederick
Cancer Research and Development Center (Frederick, MD).
HIV quantitative infectious center (QIC) assay
The quantitative infectious center (QIC) assay represents an
adaptation of the virus endpoint dilution assay. The QIC assay was
developed to investigate anti-HIV activity by test compounds
during virus adsorption/early infection and prior to cell toxicity.
Brieﬂy, virus (HIV-1 LAI or HIV-1 BAL), cells (PBMC PHA-blasts or
CEM), and test compounds were incubated for 0.5–2 h at 37 1C
(MOI¼0.02–0.05), followed by a thorough washout of drug and
inoculum. Quadruplicate aliquots of the virus-exposed cells were
serially diluted and plated into 96 well plates containing unin-
fected feeder target cells (PBMC PHA-blasts or CEM). The cells
were cultured for 5–10 days, after which the wells were scored for
the presence of viral replication using an HIV p24 antigen capture
assay. The infected cell titer (IC50 log 10) was determined using
the Reed–Meunch statistical method. The actual virus strains, MOI,
incubation times and temperatures are speciﬁed in each ﬁgure
legend.
ATP assay
Cells were plated in 96 well plates and were exposed to SIL,
SbN or drugs for varying times. Cellular ATP levels were assessed
using the ATPlite kit (Perkin Elmer).
Metabolic assessment of cells
To assess the effects of SIL and SbN on mitochondrial respira-
tion and glycolysis, we used the Seahorse XF24-3 instrument
(Seahorse Biosciences). Cells generate ATP from glucose metabo-
lism via coupled oxidative phosphorylation in mitochondria
(respiration) or via incomplete oxidation to lactic acid in the
cytosol (aerobic glycolysis). The XF24-3 Analyzer allows for inves-
tigation of cellular bioenergetic metabolism via measuring the
cellular oxygen consumption rate (OCR) (mitochondrial respira-
tion) and the extracellular acidiﬁcation rate (ECAR) which is a
surrogate for glycolysis. For each assay, CEM cells were suspended
in Seahorse Assay Medium – DMEM (unbuffered) with 25 mM
glucose, 2 mM glutamine and plated into XF24 well plates coated
with Cell-Tak (BD Biosciences) at 4  105 or 5  105 cells per well
in 100 ml. The plates were spun for 5 min at 300 g and then
placed at 37 1C for 30 min to allow the cells to attach to the plate
surface. The volume per well was increased to 700 ml with assay
medium and the plates were loaded in the instrument for
measurements after cartridge calibration. The instrument auto-
matically injected test compounds. The details are provided in
each ﬁgure legend.
Glucose uptake assay
As an estimate of glucose uptake the rate of 3H-2-deoxyglucose
(Perkin-Elmer) accumulation was measured as previously
described (Sweet et al., 2004). CEM cells were ﬁrst pre-incubated
in KRB containing 0 mM glucose for 30 min in a 5% CO2 incubator
at 37 1C. Subsequently, cells (50 μl) were transferred into 12–75
test tubes containing 140 μl of 0 mM-glucose KRB (with the
indicated additions), incubated for 5 min, and then 10 μl of 3H-2-
deoxyglucose (0.2 μCi) was added by the use of a repeater pipette
for a total incubation volume of 200 μl. At about 29 min after the
addition of 3H-2-deoxyglucose, the cell suspension was transferred
to 0.4-ml centrifuge tubes containing 100 μl of an oil mixture, and
then the free and the cell-associated radioactivity were separated
at exactly 30 min by spinning the cells through the oil layer,
freezing in liquid nitrogen and counting the cell pellet.
Statistics
Data were analyzed by Student's T tests and p values of less
than 0.05 were considered signiﬁcant.
Acknowledgments
This work was partially supported by the University of
Washington (UW) Center for AIDS Research (CFAR), a National
Institutes of Health (NIH) funded program (P30 AI027757) which
is supported by the following NIH Institutes and Centers (National
Institute of Allergy and Infectious Disease, National Cancer Insti-
tute, National Institute of Mental Health, National Institute on
Drug Abuse, National Institute of Child Health & Human Develop-
ment, National Heart, Lung, and Blood Institute, National Institute
on Aging), and by the National Center for Research Resources and
the National Center for Advancing Translational Sciences, National
Institutes of Health, through Grant UL1RR025014. This work was
also supported in part by the DRC Cell Functional Analysis Core
(National Institutes of Health Grant DK17047, to I.R.S.).
Appendix A. Supplementary materials
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2013.11.003.
J. McClure et al. / Virology 449 (2014) 96–103102
References
Agarwal, R., Agarwal, C., Ichikawa, H., Singh, R.P., Aggarwal, B.B., 2006. Anticancer
potential of silymarin: from bench to bed side. Anticancer Res. 26, 4457–4498.
Asres, K., Seyoum, A., Veeresham, C., Bucar, F., Gibbons, S., 2005. Naturally derived
anti-HIV agents. Phytother. Res. 19, 557–581.
Beinhardt, S, Rasoul-Rockenschaub, S, Maieron, A, P., Steindl-Munda, H., Hofer,
Ferenci, P., 2012. Intravenous Silibinin-therapy in patients with chronic hepa-
titis C in the transplant setting. J. Hepatol. 56, S77.
Beinhardt, S., Rasoul-Rockenschaub, S., Scherzer, T.M., Ferenci, P., 2011. Silibinin
monotherapy prevents graft infection after orthotopic liver transplantation in a
patient with chronic hepatitis C. J. Hepatol. 54, 591–592. (author reply 592-
593).
Blaising, J., Levy, P.L., Gondeau, C., Phelip, C., Varbanov, M., Teissier, E., Ruggiero, F.,
Polyak, S.J., Oberlies, N.H., Ivanovic, T., Boulant, S., Pecheur, E.I., 2013. Silibinin
inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-
dependent trafﬁcking. Cell. Microbiol..
Cheney, L., Hou, J.C., Morrison, S., Pessin, J., Steigbigel, R.T., 2011. Nef inhibits
glucose uptake in adipocytes and contributes to insulin resistance in human
immunodeﬁciency virus type I infection. J. Infect. Dis. 203, 1824–1831.
Colturato, C.P., Constantin, R.P., Maeda Jr., A.S., Yamamoto, N.S., Bracht, A., Ishii-
Iwamoto, E.L., Constantin, J., 2012. Metabolic effects of silibinin in the rat liver.
Chem. Biol. Interact. 195, 119–132.
Crabtree, H.G., 1929. Observations on the carbohydrate metabolism of tumours.
Biochem. J. 23, 536–545.
Cutrell, J., Bedimo, R., 2013. Non-AIDS-deﬁning cancers among HIV-infected
patients. Curr. HIV AIDS Rep. 10, 207–216.
Detaille, D., Sanchez, C., Sanz, N., Lopez-Novoa, J.M., Leverve, X., El-Mir, M.Y., 2008.
Interrelation between the inhibition of glycolytic ﬂux by silibinin and the
lowering of mitochondrial ROS production in perifused rat hepatocytes. Life Sci.
82, 1070–1076.
Diers, A.R., Broniowska, K.A., Chang, C.F., Hogg, N., 2012. Pyruvate fuels mitochon-
drial respiration and proliferation of breast cancer cells: effect of monocarbox-
ylate transporter inhibition. Biochem. J. 444, 561–571.
Dubrow, R., Silverberg, M.J., Park, L.S., Crothers, K., Justice, A.C., 2012. HIV infection,
aging, and immune function: implications for cancer risk and prevention. Curr.
Opin. Oncol. 24, 506–516.
Ferenci, P., Scherzer, T.M., Kerschner, H., Rutter, K., Beinhardt, S., Hofer, H.,
Schoniger-Hekele, M., Holzmann, H., Steindl-Munda, P., 2008. Silibinin is a
potent antiviral agent in patients with chronic hepatitis C not responding to
pegylated interferon/ribavirin therapy. Gastroenterology 135, 1561–1567.
Foley, G.E., Lazarus, H., Farber, S., Uzman, B.G., Boone, B.A., McCarthy, R.E., 1965.
Continuous culture of human lymphoblasts from peripheral blood of a child
with acute leukemia. Cancer 18, 522–529.
Gibson, R.M., Arts, E.J., 2012. Past, present, and future of entry inhibitors as HIV
microbicides. Curr. HIV Res. 10, 19–26.
Guigas, B., Naboulsi, R., Villanueva, G.R., Taleux, N., Lopez-Novoa, J.M., Leverve, X.M.,
El-Mir, M.Y., 2007. The ﬂavonoid silibinin decreases glucose-6-phosphate
hydrolysis in perfused rat hepatocytes by an inhibitory effect on glucose-6-
phosphatase. Cell. Physiol. Biochem. 20, 925–934.
Loisel-Meyer, S., Swainson, L., Craveiro, M., Oburoglu, L., Mongellaz, C., Costa, C.,
Martinez, M., Cosset, F.L., Battini, J.L., Herzenberg, L.A., Herzenberg, L.A., Atkuri,
K.R., Sitbon, M., Kinet, S., Verhoeyen, E., Taylor, N., 2012. Glut1-mediated
glucose transport regulates HIV infection. Proc. Natl. Acad. Sci. U.S.A. 109,
2549–2554.
McClure, J., Lovelace, E.S., Elahi, S., Maurice, N.J., Wagoner, J., Dragavon, J., Mittler, J.E.,
Kraft, Z., Stamatatos, L., Horton, H., De Rosa, S.C., Coombs, R.W., Polyak, S.J., 2012.
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation.
PLoS One 7, e41832.
Morishima, C., Shuhart, M.C., Wang, C.C., Paschal, D.M., Apodaca, M.C., Liu, Y., Sloan,
D.D., Graf, T.N., Oberlies, N.H., Lee, D.Y., Jerome, K.R., Polyak, S.J., 2010. Silymarin
inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus
infection. Gastroenterology 138 (671–681). (e671–672).
Neumann, U.P., Biermer, M., Eurich, D., Neuhaus, P., Berg, T., 2010. Successful
prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-
therapy. J. Hepatol..
Newman, D.J., Cragg, G.M., 2012. Natural products as sources of new drugs over the
30 years from 1981 to 2010. J. Nat. Prod. 75, 311–335.
Permanyer, M., Ballana, E., Este, J.A., 2010. Endocytosis of HIV: anything goes.
Trends Microbiol. 18, 543–551.
Polyak, S.J., Ferenci, P., Pawlotsky, J.M., 2013a. Hepatoprotective and antiviral
functions of silymarin components in hepatitis C virus infection. Hepatology
57, 1262–1271.
Polyak, S.J., Morishima, C., Lohmann, V., Pal, S., Lee, D.Y., Liu, Y., Graf, T.N., Oberlies,
N.H., 2010. Identiﬁcation of hepatoprotective ﬂavonolignans from silymarin.
Proc. Natl. Acad. Sci. U.S.A. 107, 5995–5999.
Polyak, S.J., Morishima, C., Shuhart, M.C., Wang, C.C., Liu, Y., Lee, D.Y., 2007.
Inhibition of T-cell inﬂammatory cytokines, hepatocyte NF-kappaB signaling,
and HCV infection by standardized Silymarin. Gastroenterology 132,
1925–1936.
Polyak, S.J., Oberlies, N.H., Pecheur, E.I., Dahari, H., Ferenci, P., Pawlotsky, J.M.,
2013b. Silymarin for HCV infection. Antiviral Ther. 18, 141–147.
Raina, K., Agarwal, C., Wadhwa, R., Serkova, N.J., Agarwal, R., 2013. Energy
deprivation by silibinin in colorectal cancer cells: a double-edged sword
targeting both apoptotic and autophagic machineries. Autophagy 9, 697–713.
Reed, L.J., Muench, H., 1938. A simple method of estimating ﬁfty percent endpoints.
Am. J. Hyg. 27, 493–497.
Sweet, I.R., Cook, D.L., Lernmark, A., Greenbaum, C.J., Wallen, A.R., Marcum, E.S.,
Stekhova, S.A., Krohn, K.A., 2004. Systematic screening of potential beta-cell
imaging agents. Biochem. Biophys. Res. Commun. 314, 976–983.
UNAIDS, 2011. AIDS at 30: nations at the crossroads. In: UNAIDS (Ed.).
UNAIDS, 2012. Together we will end AIDS. In: UNAIDS (Ed.).
von Kleist, L., Stahlschmidt, W., Bulut, H., Gromova, K., Puchkov, D., Robertson, M.J.,
MacGregor, K.A., Tomilin, N., Pechstein, A., Chau, N., Chircop, M., Sakoff, J., von
Kries, J.P., Saenger, W., Krausslich, H.G., Shupliakov, O., Robinson, P.J., McClus-
key, A., Haucke, V., 2011. Role of the clathrin terminal domain in regulating
coated pit dynamics revealed by small molecule inhibition. Cell 146, 471–484.
Wagoner, J., Morishima, C., Graf, T.N., Oberlies, N.H., Teissier, E., Pecheur, E.I., Tavis, J.
E., Polyak, S.J., 2011. Differential in vitro effects of intravenous versus oral
formulations of silibinin on the HCV life cycle and inﬂammation. PLoS One 6,
e16464.
Wagoner, J., Negash, A., Kane, O.J., Martinez, L.E., Nahmias, Y., Bourne, N., Owen, D.M.,
Grove, J., Brimacombe, C., McKeating, J.A., Pecheur, E.I., Graf, T.N., Oberlies, N.H.,
Lohmann, V., Cao, F., Tavis, J.E., Polyak, S.J., 2010. Multiple effects of silymarin on
the hepatitis C virus lifecycle. Hepatology 51, 1912–1921.
Zhan, T., Digel, M., Kuch, E.M., Stremmel, W., Fullekrug, J., 2011. Silybin and
dehydrosilybin decrease glucose uptake by inhibiting GLUT proteins. J. Cell.
Biochem. 112, 849–859.
J. McClure et al. / Virology 449 (2014) 96–103 103
